Gaithersburg, MD, United States of America

Irina A Nazarenko

USPTO Granted Patents = 21 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 6)

Average Co-Inventor Count = 3.6

ph-index = 11

Forward Citations = 889(Granted Patents)

Company Filing History:

12 out of 45

Qiagen Gaithersburg Inc.

Life Technologies Corporation

Qiagen Gaithresburg, Inc

patent

Years Active: 1997-2018

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10041117 - Primers and methods for the detection and discrimination of nucleic acids (2018-08-07),

2. 9885092 - Materials and methods for detection of HPV nucleic acids (2018-02-06),

3. 9797000 - Non-target amplification method for detection of RNA splice-forms in a sample (2017-10-24),

4. 9777264 - Materials and method for immobilizing, isolating, and concentrating cells using carboxylated surfaces (2017-10-03),

5. 9689047 - Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids (2017-06-27),

6. 9605303 - Method of determining and confirming the presence of an HPV in a sample (2017-03-28),

7. 9593366 - Individually synthesized primers to be used in whole genome amplification (2017-03-14),

8. 9422593 - Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids (2016-08-23),

9. 9115410 - Detection of nucleic acids by target-specific hybrid capture method (2015-08-25),

10. 8901287 - Detection of nucleic acids by target-specific hybrid capture method (2014-12-02),

11. 8877436 - Fast results hybrid capture assay on an automated platform (2014-11-04),

12. 8735564 - Fast results hybrid capture assay and system (2014-05-27),

13. 8394609 - Primers and methods for the detection and discrimination of nucleic acids (2013-03-12),

14. 8288520 - Fast results hybrid capture assay and system (2012-10-16),

15. 7601497 - Detection of nucleic acids by target-specific hybrid capture method (2009-10-13),

Title: The Innovative Contributions of Irina A. Nazarenko

Introduction: Irina A. Nazarenko, based in Gaithersburg, MD, is a prominent inventor in the field of molecular biology, holding a remarkable total of 21 patents. Her work primarily focuses on innovative methods and materials for the detection and analysis of nucleic acids, contributing significantly to the advancements in this critical area of research.

Latest Patents: Among her latest inventions, Irina developed novel primers and methods for the detection and discrimination of nucleic acids. This particular invention provides essential tools for identifying specific nucleic acid sequences, proving indispensable in various molecular biology applications, especially in allele-specific PCR. Another notable patent addresses materials and methods for detecting HPV nucleic acids. This invention encompasses nucleic acids designed to hybridize with HPV 16 and/or HPV 18 sequences, facilitating methods to isolate RNA from biological samples. Additionally, it enables the determination of RNA splice-form variants and gene expression, which is crucial for predicting the progression of precancerous cervical lesions.

Career Highlights: Irina has made significant contributions during her tenure at reputable organizations, including Qiagen Gaithersburg Inc. and Oncor, Inc. Her extensive experience in these companies has allowed her to advance her research and development initiatives effectively.

Collaborations: Throughout her career, Irina A. Nazarenko has collaborated with distinguished professionals, including Brian Lowe and Paul Eder. These collaborations have facilitated the exchange of ideas and expertise, leading to meaningful innovations in the realm of nucleic acid detection.

Conclusion: Irina A. Nazarenko continues to be a leading figure in molecular biology, with her inventive work paving the way for new diagnostic methods and research advancements. Her contributions not only enhance our understanding of nucleic acids but also provide critical tools for the medical and scientific communities.

This text is generated by artificial intelligence and may not be accurate.